7 completed, 1 active not recruiting. 8 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 7, Active not recruiting 1 |
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 1 | Completed 1 |
Follow Pneumococcal Vaccines: new trials by email Literature Review of Pneumococcal Vaccines trials Research Report on Pneumococcal Vaccines
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I/II Clinical Trial of 26-valent Pneumococcal Conjugate Vaccine 26-Valent pneumococcal conjugate vaccine, 23-Valent pneumococcal polysaccharide vaccine, 13-Valent pneumococcal conjugate vaccine - Pneumococcal Vaccines | Phase 1 / Phase 2 | Completed | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | 450 | 2025-07-17 | 2026-03-30 |
| A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants 0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31, 0.5 mL of the high dose VAX-31 - Pneumococcal Vaccines | Phase 2 | Active not recruiting | Vaxcyte, Inc. | 900 | 2024-11-25 | 2026-05-15 |
| Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults 31 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine - Pneumococcal Vaccines | Phase 1 / Phase 2 | Completed | Vaxcyte, Inc. | 1015 | 2023-11-08 | 2025-07-28 |
| Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine IVT PCV-25 Formulation A, IVT PCV-25 Formulation B, IVT PCV-25 Formulation C - Pneumococcal Vaccines | Phase 2 | Completed | Inventprise Inc. | 220 | 2023-10-25 | 2026-03-17 |
| Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants 0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24 - Pneumococcal Vaccines | Phase 2 | Completed | Vaxcyte, Inc. | 802 | 2023-03-29 | 2025-09-11 |
| Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults 24-Valent Pneumococcal Conjugate Vaccine, Pneumococcal 20-valent Conjugate Vaccine - Pneumococcal Vaccines | Phase 2 | Completed | Vaxcyte, Inc. | 207 | 2022-06-15 | 2024-10-09 |
| Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults 24 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine - Pneumococcal Vaccines | Phase 1 / Phase 2 | Completed | Vaxcyte, Inc. | 835 | 2022-02-22 | 2024-04-18 |
| Trial of Pneumococcal Vaccine Schedules in Ho Chi Minh City, Vietnam PCV10, PCV13 - Pneumococcal Vaccines | Phase 2 / Phase 3 | Completed | Murdoch Childrens Research Institute | 1400 | 2013-09-30 | 2022-09-14 |
Pneumococcal Infections (2) · Pneumonia (2)
Bacterial Infections (2) · Bacterial Infections and Mycoses (2) · Gram-Positive Bacterial Infections (2) · Infections (2) · Lung Diseases (2) · Respiratory Tract Diseases (2) · Respiratory Tract Infections (2) · Streptococcal Infections (2)
10-valent pneumococcal conjugate vaccine (1) · 13-valent pneumococcal vaccine (1) · 23-valent pneumococcal capsular polysaccharide vaccine (1) · PHiD-CV vaccine (1)
Vaxcyte, Inc. (5) · Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (1) · Inventprise Inc. (1) · Murdoch Childrens Research Institute (1)
United States (5) · Canada (1) · China (1) · Puerto Rico (1) · Vietnam (1)
Edward K Mulholland, MBBS, FRACP (1) · Sybil Tasker, MD, MPH, FIDSA (1)
PMID 29884695, PMID 30975525, PMID 33745731, PMID 34171233, PMID 36785850, PMID 38061367, PMID 39025698, PMID 41442837, PMID 41576705, PMID 41864214